Publications & Presentations

Prof Vela has given 35 national and international invited presentations in the last 5 years. He has spoken at multiple community engagement events including PCFA Community Conversations, PCFA support groups, Men’s Shed nights, and the QBCI Consumer Forum as part of the bladder cancer initiative that leads. In 2019 he co-led a delegation to Canberra for a “Bladder Cancer: Let’s start the conversation” event with the Parliamentary Friends of Cancer Causes.

Joshi, A., Roberts, M.J., Perera, M, ...... and Vela, I [2020] The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial. Clin Exp Metastasis.

Joshi, A., Roberts, M.J., Alinezhad, S., Williams, E.D. and Vela, I. [2020], Challenges, applications and future directions of precision medicine in prostate cancer – the role of organoids and patient‐derived xenografts. BJU Int. doi:10.1111/bju.15103

Gordon L, Elliott T, Joshi A, Williams E, Vela I, [2020] Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer, Clinical and Experimental Metastasis, 37 (2), p305-312

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman M, Lawrentschuk N, Murphy D, [2020] Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancerupdated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions, European Urology, 77 (4), p403-417

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P, Rutherford N, Martin J, Frydenberg M, Shakher R, Wong L, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, ..... , [2020] Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multi-centre study, The Lancet, 395 (10231), p1208-1216

De Bruycker A, Tran P, Achtman A, Ost P, Boutros P, Buzza M, Corcoran N, Dal Pra A, Emmenegger U, Fraser M, Hovens C, Koontz B, Lapointe J, Vela I, , [2020] Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer, World Journal of Urology, p1-10

Roberts M, Papa N, Perera M, Scott S, Teloken P, Joshi A, Vela I, Pryor D, Martin J, Woo H, [2019] A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer, BJU International, 124 (S1), p31-36

Tariq A, Khan S, Vela I, Williams E, [2019] Assessment of the use of the Internet and social media among people with bladder cancer and their carers, and the quality of available patient-centric online resources, BJU International, 123 (S5), p10-18

Pereira R, McGeorge S, Perera M, Vela I, [2019] Urachal mucinous cystadenocarcinoma, BMJ Case Reports, 12 (1), p1-4

Ahn T, Roberts M, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I, [2019] A review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC), Molecular Imaging and Biology, 21 (5), p799-807

Pereira R, Joshi A, Roberts M, Yaxley J, Vela I, [2019] Open retropubic radical prostatectomy, Translational Andrology and Urology, p1-11

Kulasinghe A, Kapeleris J, Kenny L, Warkiani M, Vela I, Thiery J, O'Byrne K, Punyadeera C, [2019] Isolation, characterization and expansion of circulating tumor cells in solid cancers, Cancer Research, 79 (13 Supp)

Kapeleris J, Kulasinghe A, Ebrahimi Warkiani M, Vela I, Kenny L, O'Byrne K, Punyadeera C, [2018] The prognostic role of circulating tumor cells (CTCs) in lung cancer, Frontiers in Oncology, 8, p1-13

Kulasinghe A, Perry C, Kenny L, Blick T, Warkiani M, Vela I, O'byrne K, Thiery J, Thompson E, Nelson C, Punyadeera C, [2018] Circulating tumor cells: The tumor trail left in the blood, Cancer Research, 78 (13S)

Saadat S, Tie B, Wood S, Vela I, Rhee H, [2018] Imaging tumour thrombus of clear cell renal cell carcinoma: FDG PET or PSMA PET? Direct in vivo comparison of two technologies, Urology Case Reports, 16, p4-5

Nicholson C, Vela I, Williams E, [2017] Prostate cancer metastasis. In AAhmad, Introduction to cancer metastasis (Cancer metastasis, Volume 1), Academic Press, p33-59

Kothari G, Louie A, Pryor D, Vela I, Lo S, Teh B, Siva S, [2017] Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases, Chinese Clinical Oncology, 6 (S2), p1-15

Gunter J, Rhee H, Sarkar P, Lee W, Philp L, Hollier B, Williams E, Vela I, Sadowski M, Lehman M, Nelson C, [2017] Targeting metabolic dysfunction induced by ADT in advance prostate cancer, Asia-Pacific Journal of Clinical Oncology, 13 (S1), p30-30

Joshi A, Nicholson C, Rhee H, Gustafson S, Miles K, Vela I, [2017] Incidental malignancies identified during staging for prostate cancer with 68Ga prostate-specific membrane antigen HBED-CC positron emission tomography imaging, Urology, 104, pe3-e4

Sternberg I, Vela I, Scardino P, [2016] Molecular profiles of prostate cancer: To treat or not to treat, Annual Review of Medicine, 67, p119-135

Rhee H, Blazak J, Tham C, Lim Ng K, Shepherd B, Lawson M, Preston J, Vela I, Thomas P, Wood S, [2016] Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour, EJNMMI Research, 6, p1-6

Teleni L, Chan R, Chan A, Isenring E, Vela I, Inder W, McCarthy A, [2016] Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials, Endocrine-Related Cancer, 23 (2), p101-112

Rhee H, Vela I, Chung E, [2016] Metabolic syndrome and prostate cancer: A review of complex interplay amongst various endocrine factors in the pathophysiology and progression of prostate cancer, Hormones and Cancer, 7 (2), p75-83

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell P, Nelson C, Chung E, Wood G, Malone G, Wood S, Heathcote P, [2016] Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer, Journal of Urology, 196 (4), p1261-1267

Tang K, Liu J, Jovanovic L, An J, Hill M, Vela I, Lee T, Ma S, Nelson C, Russell P, Clements J, Ling P, [2016] Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop, OncoTarget, 7 (4), p4939-4948

Kulasinghe A, Kenny L, Perry C, Thiery J, Jovanovic L, Vela I, Nelson C, Punyadeera C, [2016] Impact of label-free technologies in head and neck cancer circulating tumour cells, OncoTarget, 7 (44), p71223-71234

Kulasinghe A, Perry C, Ebrahimi Warkiani M, Blick T, Davies A, O'Byrne K, Thompson R, Nelson C, Vela I, Punyadeera C, [2016] Short term ex-vivo expansion of circulating head and neck tumour cells, OncoTarget, 7 (37), p60101-60109

McGrath S, Christidis D, Perera M, Hong S, Manning T, Vela I, Lawrentschuk N, [2016] Prostate cancer biomarkers: Are we hitting the mark?, Prostate International, 4 (4), p130-135

Rhee H, Lim Ng K, Tse B, Yeh M, Russell P, Nelson C, Thomas P, Samaratunga H, Vela I, Gobe G, Wood S, [2016] Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease [Correspondence], Pathology, 48 (6), p613-616

Vela I, Chen Y, [2015] Prostate cancer organoids: a potential new tool for testing drug sensitivity [Editorial], Expert Review of Anticancer Therapy, 15 (3), p261-263

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, [2014] Organoid cultures derived from patients with advanced prostate cancer, Cell, 159 (1), p176-187

Vela I, Morrissey C, Zhang X, Chen S, Corey E, Strutton G, Nelson C, Nicol D, Clements J, Gardiner E, [2014] PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer, Clinical and Experimental Metastasis, 31 (2), p199-211

Laudone, V, Vela I,[2014] Editorial Comment re: Minimally Invasive Cystectomy is Associated with Improved Perioperative Patient Safety Outcomes Compared to Open Cystectomy in a National Cohort" Urology, Volume 84, Issue 2, Pages 319-319

Vela I, et al. [2014] PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer. Clin Exp Metastasis. Feb;31(2):199-211

Laudone, V, Vela I, [2013] Editorial Comment re: "Complications Associated with Extraperitoneal Robot Assisted Radical Prostatectomy using the Standardized Martin Classification." Urology. Feb, 81, (2): 331-332

Vela, I et al. [2010]. “PITX2: a potential new target in metastatic prostate cancer”. AUA News Vol 15 issue 10

Vela, I., et al. [2007]. "Bone and prostate cancer cell interactions in metastatic prostate cancer." BJUI 99(4): 735-742.


Jan 2020

STEPS Program EAU Section of Oncological Urology (EOUS) Dublin

1 of 20 international urologists selected and first Australian

May 2017

Best of Best Plenary Podium - “Novel in vitro organoid technology to facilitate a precision medicine approach in the management of men with biochemical recurrence of prostate cancer”

Annual Scientific Meeting of the American Urologic Association, Boston, Massachusetts, USA

Sep 2011

USANZ Trainee Representative to European Urology Residents Education Programme (EUREP) Meeting in Prague, Czech Republic.

Apr 2018

USANZ Lecturer – “Precision Medicine in Localised and Early Recurrent Prostate Cancer”

Urological Association of Asia 2018 Annual Scientific Meeting, Kyoto, Japan.

May 2017

BJUI Sponsored USANZ lecture – “Personalised Medicine for Prostate Cancer”

BAUS-BJUI-USANZ Joint Session of the Annual Scientific Meeting of the American Urologic Association, Boston, Massachusetts, USA

Nov 2015

Visiting Professor

National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

May 2010

Best Poster: Prostate Cancer Basic Research IV

Annual Scientific Meeting of the American Urologic Association

May 2017

Winner 2017 ASMR Queensland Health & Medical Research Awards-Clinician Researcher Category

May 2017

PCFA Community Conversations

Brisbane, QLD, Australia

Nov 2015

Visiting Professor

Walter Reed National Military Medical Center, Bethesda, Maryland, USA

Apr 2015

Abbvie Platinum Trophy Winner


October 2009

Winner, Neville Davis Research Prize

Royal Australasian College of Surgeons


2018 – present            Uro-oncology Special Advisory Group (SAG) USANZ — Member

2017 – present            The Australian Society for Medical Research (ASMR) — Member

2017 – present            Scientific Advisory Board Healthy Male — Member

2017 ­­– present            Academy of Surgical Educators, (RACS) — Member

2016 – present            Translational Research Sub-committee ANZUP — Member

2016 – present            Prostate Cancer Sub-committee ANZUP — Member

2015 – present            European Association of Urology (EAU) — International Member

2014 – present            Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT) — Member

2014 – present            Australian Prostate Research Center - QLD (APCRC-Q) — Member

2014 – present            Translational Research Institute (TRI) — Member

2012 – present            Society of Urologic Oncology (SUO) — International Member

2012 – present            American Urological Association (AUA) — International Member

2012 – present            The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) — Member

2012 – present            Urological Society of Australia and New Zealand (USANZ) — Member

2012 – present            Royal Australasian College of Surgeons (RACS) — Fellow

Prof Vela also sits on multiple medical advisory boards for various industry bodies and multiple grant review committees for various national and international funding bodies, as well as being an invited reviewer for ten international journals.

Scroll to Top